azacitidine has been researched along with carboplatin in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Jakubowski, A; Kritz, AD; Maslak, P; Menendez-Botet, C; Raptis, G | 1 |
| Brown, R; Kaye, SB; Plumb, JA; Sludden, J; Strathdee, G | 1 |
| Aird, RE; Chen, H; Cummings, J; Jodrell, DI; Morris, RE; Muir, M; Ritchie, AA; Sadler, PJ | 1 |
| Gottesman, MM; Liang, XJ; Pai-Panandiker, A; Shen, DW; Su, A | 1 |
| Appleton, K; Barrett, S; Bellenger, K; Brown, R; Jadayel, D; Judson, I; Kaye, SB; Lee, C; Mackay, HJ; Mackay, L; McCormick, C; Plumb, JA; Reade, S; Schätzlein, A; Setanoians, A; Strathdee, G; Tang, A; Twelves, C | 1 |
| Fu, S; Hu, W; Kavanagh, JJ; Li, Y; Shen, DY | 1 |
| Karp, J | 1 |
| Balch, C; Breen, T; Fang, F; Kulesavage, C; Li, L; Matei, DE; Nephew, KP; Schilder, J; Shen, C; Snyder, AJ; Zhang, S | 1 |
| Bast, RC; Coleman, RL; Fu, S; Gershenson, DM; Hennessy, BT; Hu, W; Iyer, R; Kavanagh, JJ; Kurzrock, R; Levenback, CF; Markman, M; Sood, AK; Wolf, JK | 1 |
| Arnold, A; Berry, WA; Fang, F; Huang, T; Matei, D; Nephew, KP; Schilder, J; Shen, C; Zeng, Y | 1 |
| Bustinza-Linares, E; Falchook, GS; Fu, S; Hong, DS; Hu, W; Kurzrock, R; Moulder, S; Naing, A; Parkhurst, KL; Sood, AK; Wheler, JJ | 1 |
| Appleton, K; Brown, R; Gabra, H; Glasspool, RM; Gore, ME; Halford, SE; Hall, GD; Kaye, S; Mackean, M; McNeish, IA; Paul, J; Pledge, S; Rustin, GJ; Ullah, R; Walker, J; Wilson, RH | 1 |
| Fang, F; Li, M; Matei, D; Nephew, KP; Pilrose, J; Shen, C; Wang, Y; Wulfridge, P; Zuo, Q | 1 |
| Cardenas, H; Condello, S; Fang, F; Liu, Y; Matei, D; Nephew, KP; Segar, M; Taverna, P; Wang, Y | 1 |
| Benson, EA; Liu, Y; Matei, D; Nephew, KP; Skaar, TC | 1 |
| Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H | 1 |
| Bowden, NA; Budden, T; van der Westhuizen, A | 1 |
| Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B | 1 |
| Beller, M; Hein, JI; Junghanß, C; Murua Escobar, H; Nolte, I; Schille, JT; Weiner, F; Wu, XF | 1 |
| Bowden, NA; van der Westhuizen, A; Wong-Brown, MW | 1 |
| Althouse, S; Gentzler, R; Jalal, SI; Kalra, M; Mamdani, H; Perkins, S; Wei, CX | 1 |
1 review(s) available for azacitidine and carboplatin
| Article | Year |
|---|---|
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic | 2017 |
10 trial(s) available for azacitidine and carboplatin
| Article | Year |
|---|---|
Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Female; Humans; Leukemia; Male; Middle Aged; Pilot Projects; Recurrence | 1996 |
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Azacitidine; Carboplatin; Cohort Studies; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Humans; Male; Middle Aged; Neoplasms | 2007 |
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; DNA Methylation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds | 2010 |
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2011 |
Epigenetic resensitization to platinum in ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; Disease-Free Survival; DNA Methylation; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms | 2012 |
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Topics: Acetylation; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; DNA Methylation; Female; Histone Deacetylase Inhibitors; Histones; Humans; Male; Middle Aged; Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Valproic Acid | 2013 |
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; MutL Protein Homolog 1; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Platinum | 2014 |
Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Carboplatin; Decitabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Pilot Projects; Prognosis; Survival Rate; Young Adult | 2015 |
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome | 2020 |
A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |
10 other study(ies) available for azacitidine and carboplatin
| Article | Year |
|---|---|
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Base Pair Mismatch; Carboplatin; Carrier Proteins; Cisplatin; Colonic Neoplasms; Dacarbazine; Decitabine; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Ovarian Neoplasms; Promoter Regions, Genetic; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Calcium Channel Blockers; Carboplatin; Cisplatin; Decitabine; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Edetic Acid; Female; Humans; Ligands; Mice; Mice, Nude; Neoplasm Proteins; Organometallic Compounds; Ovarian Neoplasms; Ruthenium Compounds; Structure-Activity Relationship; Verapamil; Xenograft Model Antitumor Assays | 2002 |
Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells.
Topics: Antineoplastic Agents; Azacitidine; Carboplatin; Carrier Proteins; Cell Survival; Cisplatin; Decitabine; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Endocytosis; Folate Receptors, GPI-Anchored; Folic Acid; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Methotrexate; Monomeric GTP-Binding Proteins; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2004 |
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carboplatin; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms | 2009 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Decitabine reactivated pathways in platinum resistant ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Gene Expression Profiling; Humans; Ovarian Neoplasms | 2014 |
Epigenetic targeting of ovarian cancer stem cells.
Topics: Aldehyde Dehydrogenase; Animals; Azacitidine; Carboplatin; Cell Differentiation; Cell Line, Tumor; DNA Methylation; Epigenesis, Genetic; Epigenomics; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Ovarian Neoplasms | 2014 |
Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carboplatin; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Damage; DNA Methylation; DNA Repair; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Melanoma; Promoter Regions, Genetic | 2018 |
Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Carboplatin; Cell Count; Cell Line, Tumor; Cell Survival; Dichloroacetic Acid; Doxorubicin; Drug Synergism; Humans; Isoquinolines; Male; Prostatic Neoplasms | 2021 |
Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Cell Growth Processes; Cell Line, Tumor; DNA Methylation; Female; Humans; Immune Checkpoint Inhibitors; Immunity; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Signal Transduction; Up-Regulation | 2022 |